期刊文献+

血清半乳糖凝集素-3水平与2型糖尿病患者合并冠心病的相关性研究 被引量:3

Serum galectin levels associated with the presence of coronary artery disease in patients with type 2 diabetes
下载PDF
导出
摘要 目的:本研究旨在探讨血清半乳糖凝集素-3水平与2型糖尿病患者合并冠心病的相关性。方法本研究共纳入177例2型糖尿病患者,根据患者是否罹患冠心病将所有患者分为冠心病组(D-CAD+,n=65)及非冠心病组(D-CAD-,n=112),另选取单纯冠心病患者(CAD+,n=73)及健康成人(ND,n=50)作为对照组。采用酶联免疫吸附(ELISA)法测量各组血清半乳糖凝集素-3水平。结果D-CAD+组患者血清Gal-3水平表达最高(10.27±2.53)ng/ml,其次为CAD+组(5.72±0.64)ng/ml,再次为D-CAD-组(2.64±0.36)ng/ml,ND组表达最低(1.17±0.21)ng/ml。D-CAD+组患者血清Gal-3表达水平较CAD+组显著升高,而后者显著高于D-CAD-组,同时上述三组均高于ND组,差异均有统计学意义(P<0.05)。多元Logistic回归分析显示高血清半乳糖凝集素-3水平与2型糖尿病患者存在冠心病呈独立相关(优势比2.375,95%可信区间1.258~3.952;P<0.01)。结论血清半乳糖凝集素-3水平是预测2型糖尿病患者合并冠心病的独立危险因子,血清半乳糖凝集素-3有望可能成为预测2型糖尿病患者发生冠心病风险的重要的生物学标记物。 Objective To explore whether serum galectin-3 (Gal-3) levels are associated with the presence of coronary artery disease (CAD) in patients with type 2 diabetes (DM2). Method A total of 177 patients with DM2 were enrolled in the present study. All the patients were classified as D-CAD+ (n=65) or D-CAD- (n=112) group based on the presence of CAD or not.73 patients with CAD and 50 healthy adults served as the control group. Serum Gal-3 levels were determined by enzyme-linked immunosorbent assay (ELISA).Result The highest serum Gal-3 expression level of (10.27±2.53)ng/ml was present in D-CAD+ patients, followed by the CAD+ patients with the level of (5.72±0.64)ng/ml and the D-CAD- patients with the level of (2.64 ±0.36)ng/ml, while the lowest one of (1.17±0.21)ng/ml was present in healthy adults. D-CAD+patients had significantly higher Serum Gal-3 levels than CAD+ patients, and the latter had significantly higher Serum Gal-3 levels than D-CAD- patients. Serum Gal-3 levels in all three groups above were significantly higher in healthy adults, which presented statistically significant differences (P<0.05).Multivariate logistic regression demonstrated that higher Gal-3 levels were independently associated with the presence of CAD (OR 2.375, 95% CI 1.258~3.952,P<0.01) in patients with DM2.Conclusion Serum Gal-3 is an independent risk factor for CAD in DM2 patients, which indicates that Gal-3 might be a useful biomarker for predicting the presence of CAD in patients with DM2.
作者 林璋 林晓红
出处 《创伤与急诊电子杂志》 2015年第2期13-16,共4页 Journal of Trauma and Emergency(Electronic Version)
关键词 2型糖尿病 冠心病 半乳糖凝集素-3 生物学标记物 GALECTIN-3 Type 2 diabetes Coronary artery disease Biomarker
  • 相关文献

参考文献11

  • 1Berry C,Tardif JC,Bourasea MG. Coronary heart disease in patients with diabetes[J].Journal of the American College of Cardiology,2007,631-642.
  • 2Zellweger MJ. Prognostic significance of silent coronary artery disease in type 2 diabetes [J]. Herz,2006, 31 (3):240-245.
  • 3Pradhan AD,Ridker PM.Do atheroscterosis and type 2 diabetes share a common inflammatory basis?[J].European Heart Journal,2002,23(11):831-834.
  • 4de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression[J]. Eur J Heart Fail,2009,11 (9):811-817.
  • 5Falcone C,Lucibello S,Mazzucehelli I,et al. Galectin-3 plasma levels and coronary artery disease:a new possible biomarker of acute coronary syndrome[J].International Journal of Immunopathology and Pharmacology,2011, 4:905-913.
  • 6陈协兴,洪华山,陈良龙,郑关毅,王一波,江琼,董现锋.慢性心力衰竭患者6min步行试验与血清脑利钠肽水平的临床研究[J].中国临床药理学与治疗学,2004,9(5):561-564. 被引量:21
  • 7Reifenberg K, Lehr HA, Torzewski M,et al. Interferon-g induces chronic active myocarditis and cardiomyopathy in transgenic mice[J]. Am J Pathol,2007,171:463-472.
  • 8Papaspyridonos M,McNeill E,de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction[J].Arterioscle- rosis,Thrombosis,and Vascular Biology,2008, 3:433-440.
  • 9Suzuki Y, Inoue T, Yoshimaru T, et al. Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitoehondrial permeability transition[J].Biochim Biophys Acta,2008,1783(5):924-934.
  • 10Nachtigal M,AI-Assaad Z,Mayer EP, et al.Galectin-3 expression in human atherosclerotic lesions[J].American Journal of Pathology, 1998,5:1199-1208.

二级参考文献13

  • 1Maisel AS;Krishnaswamy P;Nowak RM;McCord J, Hollander JE, Duc P.Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J],2002(03).
  • 2Harrison A;Morrison LK;Krishnaswamy P;Kazanegra R, Clopton P, Dao Q.B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea[J],2002(02).
  • 3Guyatt GH;Sullivan MJ;Thompson PJ.The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure,1985(08).
  • 4Bittner V;Weiner DH;Yusuf S.Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigtors[J],1993(14).
  • 5Peeters P;Mets T.The 6-minute walk as appropriate exercise test in elderly patients with chronic heart failure,1996(04).
  • 6Cahalin LP;Mathier MA;Semigran MJ;Dec GW,DiSalvo TG.The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure[J],1996(02).
  • 7McDonagh TA;Robb SD;Murdoch DR;Morton JJ, Ford I, Morrison CE.Biochemical detection of left ventricular systolic dysfunction[J],1998(9095).
  • 8Maisel A.B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure[J],2002(20).
  • 9Shah MR;Hasselblad V;Gheorghiade M;Adams KF, Swedberg K, Califf RM.Prognostic usefulness of six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy,2001(09).
  • 10慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2414

共引文献20

同被引文献22

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部